The TRIUMPH program includes seven other Phase 3 trials (TRIUMPH-1 general obesity 80 weeks, TRIUMPH-2 obesity+T2D, TRIUMPH-3 obesity+CV disease, plus T2D, OSA, and CVOT) with readouts expected during 2026
Other GLP-1 medications and their dosing flexibility Understanding how other medications in the same class handle dose timing provides useful context for tirzepatide users
If such reactions occur, discontinue use and seek medical attention
Rua Da Bayer, COIMBRA, Portugal 3045-016 FDA-07 Revised January 2022 or MADE IN INDIA FDA-10 Revised: November 2024 BIONPHARMA NDC 69452-171-13 Azithromycin Tablets, USP 250 mg Rx only 30 Tablets BIONPHARMA NDC 69452-172-13 Azithromycin Tablets, USP 500 mg Rx only 30 Tablets
doi: 10.1186/s12933-022-01604-7